Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors

Transport of endocannabinoids across the plasma membrane and within the cell

(2013) Christopher J. Fowler   FEBS Journal

Multiple Functions of Endocannabinoid Signaling in the Brain

(2012) István Katona et al.   Annual Review of Neuroscience

Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system

(2012) Bright N Okine et al.   BRITISH JOURNAL OF PHARMACOLOGY

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial

(2012) J. Corey-Bloom et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial

(2012) John Peter Zajicek et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee

(2012) John P. Huggins et al.   PAIN

The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis

(2012) David Baker et al.   Multiple Sclerosis and Related Disorders

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

Fatty Acid-binding Proteins TransportN-Acylethanolamines to Nuclear Receptors and Are Targets of Endocannabinoid Transport Inhibitors

(2011) Martin Kaczocha et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings

(2011) Magnhild Sandberg-Wollheim et al.   Multiple Sclerosis Journal

A catalytically silent FAAH-1 variant drives anandamide transport in neurons

(2011) Jin Fu et al.   NATURE NEUROSCIENCE

Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse

(2011) Sarah Al-Izki et al.   Multiple Sclerosis and Related Disorders

Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system

(2010) Joel E Schlosburg et al.   NATURE NEUROSCIENCE

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2

(2010) R. G. Pertwee et al.   PHARMACOLOGICAL REVIEWS

Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects

(2008) Jonathan Z Long et al.   Nature Chemical Biology

Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis

(2008) Michael Webb et al.   NEUROSCIENCE LETTERS

Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors

(2007) G Pryce et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis

(2007) J. Ludovic Croxford et al.   JOURNAL OF NEUROIMMUNOLOGY